Akebia Therapeutics Set for Breakout Amid Strong Clinical Outcomes
AI Prediction of Akebia Therapeutics (AKBA)
Akebia Therapeutics is poised for significant stock movement due to recent positive developments and upcoming catalysts. The company's robust pipeline, particularly Vafseo's performance and potential FDA approvals, could drive investor interest and stock valuation in the near term.
AKBA Report Information
Prediction Date2025-07-03
Close @ Prediction$3.62
Mkt Cap982m
IPO DateN/a
AI-derived Information
Recent News for AKBA
- Apr 13, 8:00 am — Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 (GlobeNewswire)
- Apr 7, 8:00 am — Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium (GlobeNewswire)
- Apr 2, 4:05 pm — Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Apr 1, 4:05 pm — Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors (GlobeNewswire)
- Mar 19, 4:05 pm — Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 (GlobeNewswire)
- Mar 3, 8:00 am — Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire)
- Mar 2, 4:05 pm — Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Feb 27, 8:30 am — Akebia Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
- Feb 26, 4:14 pm — Akebia Therapeutics Inc (AKBA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com)
- Feb 26, 9:16 am — Akebia Therapeutics Q4 Earnings Call Highlights (MarketBeat)
- Feb 26, 7:30 am — Akebia Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
- Feb 26, 7:00 am — Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights (GlobeNewswire)
NDAPR (News-Driven AI Prediction Revision) events for AKBA
No NDAPR events found.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.